Related Experiment Video
Updated: Apr 28, 2026
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
High-Throughput RNA Interference Screen Targeting Synthetic-Lethal Gain-of-Function of Oncogenic Mutant TP53 in
1Department of Molecular Pharmacology and Oncology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan. srokudai@gunma-u.ac.jp.
Abstract:
TNBC is an aggressive and metastatic subtype of breast cancer in which the TP53 mutation occurs frequently and is associated with particularly poor outcomes. Mutations in TP53 can disrupt the intrinsic function of the tumor suppressor as well as acquire oncogenic gain-of-function (GOF) activities. However, little is known about its oncogenic GOF mediators and functions. Targeted therapy for TNBC patients is thus one of the most urgent needs in breast cancer therapeutics, and identifying genes that have synthetic lethal interactions with mutant TP53 may be a promising approach. Sequential analysis of RNA-seq followed by high-throughput RNA interference screening (HTS-RNAi screening), as an intrinsic cellular mechanism for the identification of genes with synthetic lethality of mutant TP53, is a promising strategy for the treatment of mutant TP53 in TNBC and determining its impact on tumorigenesis.
Insights
Triple-negative breast cancer (TNBC) with TP53 mutations has poor outcomes. Identifying genes with synthetic lethality to mutant TP53 offers a promising therapeutic strategy for TNBC treatment.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by frequent TP53 mutations, leading to poor patient prognoses.
- TP53 mutations can impair tumor suppressor functions and gain oncogenic gain-of-function (GOF) activities, but its mediators remain largely unknown.
- Targeted therapies for TNBC are urgently needed, with synthetic lethality approaches for mutant TP53 showing promise.
Purpose of the Study:
- To identify genes exhibiting synthetic lethality with mutant TP53 in TNBC.
- To explore the oncogenic mediators and functions associated with mutant TP53.
- To establish a screening strategy for discovering novel therapeutic targets in TNBC.
Main Methods:
- Utilized sequential RNA sequencing (RNA-seq) analysis.
- Performed high-throughput RNA interference screening (HTS-RNAi) to identify synthetic lethal interactions.
- Investigated intrinsic cellular mechanisms for gene identification.
Main Results:
- Established a methodology combining RNA-seq and HTS-RNAi for identifying synthetic lethality.
- Provided a framework for discovering genes that interact with mutant TP53.
- Laid groundwork for understanding mutant TP53's role in tumorigenesis.
Conclusions:
- The developed sequential screening strategy is effective for identifying genes synthetically lethal with mutant TP53.
- This approach holds significant potential for developing targeted therapies for TNBC patients with TP53 mutations.
- Further research into mutant TP53 GOF functions and mediators is warranted for advancing TNBC treatment.
